About the Industry:

 Indian Pharma companies spend 8-13 percent of their total turnover in R&D
 India’s pharma export market is thriving due to its strong presence in the generics
space
 India's generic drugs account for 20 per cent of global exports in terms of volume,
making it the largest provider of generic medicines globally
 Pharmaceutical export from India, which include bulk drugs, intermediates, drug
formulations, biologicals, Ayush & herbal products and surgical
 Pharmaceutical exports from India stood at USD 16.28 billion in FY20 and US$ 1.53
billion in April 2020
 Indian pharmaceutical sector supplies over 50 per cent of global demand for various
vaccines, 40 per cent of generic demand in the US and 25 per cent of all medicine in
the UK
 The biggest export destination for Indian pharma product is the US. In FY20, 32.1 per
cent of India's pharma exports were to the North America, followed by 17.98 per
cent to Africa and 15.70 per cent to the European Union
 In May 2020, the Indian Pharmaceutical sales grew 9 percent y-o-y to Rs 10,342
crore (US$ 1.47 bn)
 Medicine spending in India is projected to grow 9-12 per cent over the next five
years, leading India to become one of the top 10 countries of medicine spending
 India’s cost of production is significantly lower than that of the US and almost half of
that of Europe. It gives a competitive edge to India over others
 Pharma companies have increased spending to tap rural markets and develop better
medical infrastructure
 The India OTC market is expected to reach US$ 10.22 billion by 2024
 Hospitals' market size is expected to increase by US$ 200 billion by 2024
 Medical devices industry is expected to reach US$ 50 billion by 2025
 Major market leaders in this industry include Pfizer, Sanofi, GlaxoSmithKline, Merc &
Co Inc. with all their headquarters located in Mumbai
 The Union Cabinet has given its nod for the amendment of existing Foreign Direct
Investment (FDI) policy in the pharmaceutical sector in order to allow FDI up to 100
per cent under the automatic route for manufacturing of medical devices subject to
certain conditions
 India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost
to companies to manufacture pharmaceutical ingredients domestically by 2023
 Under Budget 2020-21, Rs 65,012 crore (US$ 9.30 billion) has been allocated to the
Ministry of Health and Family Welfare is. The Government has allocated Rs 34,115
crore (US$ 4.88 billion) towards the National Health Mission under which rural and
urban people will get benefited
 The Government of India is planning to set up an electronic platform to regulate
online pharmacies under a new policy to stop any misuse due to easy availability
 Government of India unveiled 'Pharma Vision 2020' to make India a global leader in
end-to-end drug manufacture. Approval time for new facilities has been reduced to
boost investment
 Indian pharmaceutical facilities can sell drugs in the US only after it has been
inspected and approved by the US FDA. With the ban on international travel,
inspection is out of question, rendering it impossible for Indian drug companies to
sell in the US and other overseas market
 The pandemic has also forced generic drug manufacturers, both contract and
captive, to delay their plans for new product launches